FDA Defines Ground Rules For Evolving DES Clinical Trial Paradigm
This article was originally published in The Gray Sheet
Executive Summary
Foreign drug-eluting stent trial strategies should be discussed with FDA at pre-IDE meetings to ensure that data outside the U.S. will be acceptable for premarket submissions, CDRH Division of Cardiovascular Devices Director Bram Zuckerman recommends